GEHCV GE HEALTHCARE TECHNOLOGIES INC

GE HealthCare Showcases the Latest AI-enhanced Radiation Therapy Solutions at ASTRO 2024

GE HealthCare (Nasdaq: GEHC) today announced its latest innovations in radiation oncology that will be showcased at the American Society for Radiation Oncology (ASTRO) 2024 conference in Washington, DC. These novel solutions aim to improve the entirety of the radiation therapy workflow for clinicians and cancer patients.

It is estimated that 470,000 patients receive radiotherapy each year in the U.S. and more than half of patients with cancer will receive radiotherapy.i The silver lining is, that in recent years, improvements in diagnosis, therapy, and supportive care have led to increasing numbers of cancer survivors.i The innovations showcased at ASTRO are helping clinicians more efficiently navigate the complex oncology care pathway, ultimately enabling truncated timelines from diagnosis to treatment, which are critical for improved patient outcomes.

GE HealthCare will be showcasing the following radiation oncology solutions at ASTRO 2024:

  • Intelligent Radiation Therapy (iRT): Designed to enable multi-vendor system interoperability, connectivity, and efficiency throughout the radiation oncology care continuum. The artificial intelligence (AI)-enhanced iRT includes key features such as an integrated workflow that connects hardware and software vendors, as well as various applications, into an intuitive single interface.
  • Revolution™ RT: Recently , this new system enables precision radiation therapy simulation and includes a wide-bore CT (computed tomography) platform and high-performance radiation therapy simulation, diagnostic, and interventional capabilities. The technology’s capabilities are now further enhanced with GE HealthCare’s MIM Software solutions.
  • MIM Maestro and Contour ProtégéAI+: A range of interoperable technologies from GE HealthCare’s MIM Software (), including Contour ProtégéAI+ for zero-click AI auto-contouring and MIM Maestro for easier reirradiation, faster simulation-to-treatment times, and better target volumes.
  • Prostate Volume Assist: AI software available on ultrasound-guided active imaging systems designed to automate the process for generating prostate volume measurements.
  • StarGuide™: A digital SPECT (Single Photon Emission Computed Tomography)/CT offering clinicians unique opportunities to make personalized care decisions and treatment response assessments that are at the heart of Theranostics, which combines cancer treatment with diagnostic tools that help precisely diagnose and monitor disease.

“We are innovating to solve the greatest challenges in radiation oncology and aiming to provide more complete understanding of the data that inform key clinical decisions throughout the care pathway,” says Dr. Ben Newton, GE HealthCare’s general manager for Oncology Solutions. “Our portfolio of deep learning-based interoperable solutions includes innovations that span from pre-treatment planning to post-treatment imaging, featuring AI-enhanced solutions that connect and optimize workflows to better curate and synthesize complex data and allow clinicians to focus more of their time on patient care.”

Intelligent Radiation Therapy (iRT)

Top healthcare institutions across the globe – from the United States to India – have begun to use iRT to upgrade the workflow for patients undergoing radiation therapy. iRT’s multi-vendor data orchestration capabilities provide standardization of complex workflows, which could enable a shorter timeline to treatment for patients. Additionally, iRT is designed to manage advanced imaging and machine learning algorithms, which in turn help to enable more precise targeting of tumors while aiming to minimize damage to surrounding healthy tissues. The recently enhanced iRT solution includes an Instaplan feature (with RaySearch) that creates a treatment plan while the patient is still on the simulation table. This is a paradigm shift that could potentially reduce the critical time between simulation and first radiation dose. It also features MR Direct (with Spectronic Medical), which is integrated into iRT, and harnesses the power of AI to convert MR simulation images into an equivalent CT image that can be used for RT dose calculation. Simplified Planning (through MIM Software) within iRT also allows for advanced interoperability with automated context launching to simplify pre-treatment planning steps including image viewing, segmentation, and fusion.

At ASTRO 2024, GE HealthCare and MIM Software will be hosting two lunch symposiums, including:

  • “Data-Enhanced Strategies in Improving Radiation Therapy Outcomes” on September 29 at 12pm EST in Room 154 of the Walter E. Washington Convention Center.
  • “Reducing Time to Treatment with MIM Software” on October 1 at 12pm EST in Room 154 at the Walter E. Washington Convention Center.

To learn more about GE HealthCare’s oncology care solutions, please visit booth #713 (GE HealthCare) and booth #1511 (GE HealthCare’s MIM Software) or visit . GE HealthCare’s immersive experience booth will be organized around the patient care journey, emphasizing diagnosis, planning, treatment, and follow-up, as well as featuring the company’s latest advancements and ecosystem partners at each stage. In addition, GE HealthCare will host various “Meet the Experts” sessions at the booth.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on , , , , and for the latest news, or visit our website for more information.

i Deborah E. Citrin, M.D. Recent Developments in Radiotherapy. Published September 14, 2017. N Engl J Med 2017;377:1065-1075, DOI: 10.1056/NEJMra1608986 VOL. 377 NO. 11. Available at: . Last accessed September 2024.

EN
26/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GE HEALTHCARE TECHNOLOGIES INC

Moody's Ratings assigns Baa2 rating to GE Healthcare's sr. notes; stab...

Moody's Ratings (Moody's) assigned a Baa2 rating to GE HealthCare Technologies Inc.'s ("GE HealthCare") proposed offering of senior unsecured notes. There are no changes to GE HealthCare's existing ratings including the Baa2 issuer rating, Baa2 senior unsecured notes ratings and (P)Baa2 senior unsec...

 PRESS RELEASE

GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premiu...

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on patients with dense breasts. Approximately 71% of cancers occur in dense breasts.1 According to studies across the U.S. and Europe, 40% of women2 and 70% of Asian women3 have dense breast tissue, making them four to six times more likely to receive a breast cancer diagnosis.4 Early d...

 PRESS RELEASE

GE HealthCare and NVIDIA reimagine diagnostic imaging with autonomous ...

SAN JOSE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced a collaboration with NVIDIA at GTC 2025, expanding the existing relationship between the two companies to focus on pioneering innovation in autonomous imaging, beginning with autonomous X-ray technologies and autonomous applications within ultrasound. GE HealthCare has been at the forefront of medical technology innovation with a series of “firsts” that date back more than a century, starting with the invention of its X-ray tube, followed by several others including the first handheld ultrasound, first 3D obstetr...

 PRESS RELEASE

GE HealthCare expands invasive cardiology solutions portfolio with Alt...

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards. Cardiovascular disease (CVD) has nearly doubled over the past three decades, affecting more than 500 ...

 PRESS RELEASE

GE HealthCare Advances Its Cloud Strategy by Unveiling the Genesis Por...

LAS VEGAS--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced its new Genesis solutions, a portfolio of cloud enterprise imaging software-as-a-service (SaaS) solutions. Four features will be offered when commercially released – edge, storage, vendor neutral archive and data migration.i These cloud solutions, are designed to help enhance healthcare organizations’ efficiency and precision, streamline workflows, and optimize the use of capital and IT resources. The growing volume and complexity of patient cases are putting increasing pressure on hospitals’ IT systems, driving the ne...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch